Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

RAPT Therapeutics

NASDAQ RAPT
$4.04 0.0000 0.0000%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 14 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

156.05M
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
111.02M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
38.63M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-83.74 %

Upcoming events RAPT Therapeutics

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart RAPT Therapeutics

Stock analysis RAPT Therapeutics

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-1.32 28.88
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.
1.06 4.03
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-0.88 11.32
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.36 0.25
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-90.23 10.75

Price change RAPT Therapeutics per year

14.89$ 41.86$
Min Max

Summary analysis RAPT Therapeutics

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure RAPT Therapeutics

Revenue and net income RAPT Therapeutics

All parameters

Stock news RAPT Therapeutics

All news
20 February в 17:35

RAPT Therapeutics Stock Is Down 68%. FDA Halts 2 Studies After Liver Failure.

20 February в 16:50

RAPT Therapeutics Shares Plunge Premarket on FDA Study Hold

20 February в 16:45

RAPT Therapeutics Shares Plunge Premarket on FDA Study Hold

20 February в 16:40

RAPT Therapeutics’ stock plunges as FDA halts two clinical trials

20 February в 15:49

Two RAPT Therapeutics Studies Put on Hold by FDA After Adverse Event

20 February в 15:49

Two RAPT Therapeutics Studies Put on Hold by FDA After Adverse Event

14 March 2023 в 18:05

RAPT Therapeutics Shares Slide on Atopic Dermatitis Study Delay >RAPT

14 March 2023 в 18:05

RAPT Therapeutics Shares Slide on Atopic Dermatitis Study Delay >RAPT

18 November 2022 в 19:00

RAPT Therapeutics Shares Drop 11% After Public Offering Prices

18 November 2022 в 19:00

RAPT Therapeutics Shares Drop 11% After Public Offering Prices

9 December 2021 в 15:35

RAPT Therapeutics started at overweight with $61 stock price target at J.P. Morgan

About company RAPT Therapeutics

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Address:
561 Eccles Avenue, South San Francisco, CA, United States, 94080
Company name: RAPT Therapeutics
Issuer ticker: RAPT
ISIN: US75382E1091
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2019-10-31
Sector: Healthcare
Industry: Biotechnology
Site: https://www.rapt.com

On which stock exchange are RAPT Therapeutics (RAPT) stocks traded?

RAPT Therapeutics (RAPT) stocks are traded on NASDAQ.

What is the ticker of RAPT Therapeutics stocks (RAPT)?

The stock ticker of RAPT Therapeutics’s stocks or in other words, the code is RAPT. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does RAPT Therapeutics (RAPT) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, RAPT Therapeutics (RAPT) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are RAPT Therapeutics (RAPT) stocks traded?

RAPT Therapeutics (RAPT) stocks are traded on the NASDAQ exchange in dollars.

What is the price of RAPT Therapeutics (RAPT) stocks today?

The current price of RAPT Therapeutics stocks on 20.05.2024 is 4.04 dollars. per share.

What is the dynamics of RAPT Therapeutics (RAPT) stocks from the beginning of the year?

RAPT Therapeutics (RAPT) quotes have increased by -83.37% from the beginning of the year up to 4.04 dollars. per 1 stocks.

How much did RAPT Therapeutics (RAPT) stocks increase in мае 2024?

This month RAPT Therapeutics (RAPT) quotes have increased by -50.61% to 4.04 dollars. per share.

How much are RAPT Therapeutics (RAPT) stocks worth?

Today, on October, 20.05.2024 RAPT Therapeutics’s (RAPT) stocks cost 4.04 dollars..

What is the market capitalization of RAPT Therapeutics (RAPT)?

Capitalization is the market value of RAPT Therapeutics (RAPT) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 20.05.2024, the market capitalization of RAPT Therapeutics (RAPT) is estimated at about 156046475 dollars.